[go: up one dir, main page]

MX2019004842A - Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. - Google Patents

Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.

Info

Publication number
MX2019004842A
MX2019004842A MX2019004842A MX2019004842A MX2019004842A MX 2019004842 A MX2019004842 A MX 2019004842A MX 2019004842 A MX2019004842 A MX 2019004842A MX 2019004842 A MX2019004842 A MX 2019004842A MX 2019004842 A MX2019004842 A MX 2019004842A
Authority
MX
Mexico
Prior art keywords
phosphoinositide
pharmaceutically acceptable
combination therapy
kinase inhibitor
binding moiety
Prior art date
Application number
MX2019004842A
Other languages
English (en)
Inventor
Fattaey Ali
W Rhyasen Garrett
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of MX2019004842A publication Critical patent/MX2019004842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un método para tratar el cáncer en un sujeto que lo necesita, que comprende administrar al sujeto: (a) un compuesto de la Fórmula I: (ver fórmula) o una sal farmacéuticamente aceptable de este, donde R es hidrógeno o un grupo acilo; y (b) un inhibidor BCL-2; donde el compuesto de la Fórmula I o una sal farmacéuticamente aceptable de este y un inhibidor BCL-2 se administran en cantidades que en combinación son terapéuticamente eficaces. La invención también proporciona una composición farmacéutica que comprende un compuesto de la Fórmula I o una sal farmacéuticamente aceptable de este, un inhibidor BCL-2 y un portador o excipiente farmacéuticamente aceptable.
MX2019004842A 2016-11-02 2017-11-01 Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. MX2019004842A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416329P 2016-11-02 2016-11-02
PCT/US2017/059464 WO2018085342A1 (en) 2016-11-02 2017-11-01 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
MX2019004842A true MX2019004842A (es) 2019-06-20

Family

ID=62076339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004842A MX2019004842A (es) 2016-11-02 2017-11-01 Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.

Country Status (15)

Country Link
US (1) US20180133223A1 (es)
EP (1) EP3535272A4 (es)
JP (1) JP2020500175A (es)
KR (1) KR20190077040A (es)
CN (1) CN109923117A (es)
AU (2) AU2017355385A1 (es)
BR (1) BR112019008698A2 (es)
CA (1) CA3040727A1 (es)
EA (1) EA201991069A1 (es)
IL (1) IL266135A (es)
MA (1) MA46728A (es)
MX (1) MX2019004842A (es)
PH (1) PH12019500858A1 (es)
SG (1) SG11201903723RA (es)
WO (1) WO2018085342A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02451B (me) 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
WO2020055840A1 (en) * 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN112778212B (zh) * 2021-01-28 2022-03-15 苏州莱克施德药业有限公司 库潘尼西中间体2-胺基嘧啶-5-羧酸甲酯的合成方法
CN117865979A (zh) * 2024-01-04 2024-04-12 广州必贝特医药股份有限公司 噻吩嘧啶类化合物的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152188A1 (en) * 2005-08-05 2010-06-17 Akella Satya Surya Visweswara Srinivas Novel Heterocyclic Compounds
EP2114949A1 (en) * 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
ME02451B (me) * 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
JP6123097B2 (ja) * 2012-10-10 2017-05-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト チエノピリミジン化合物を製造するための方法
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
US20150320755A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
CA3040727A1 (en) 2018-05-11
AU2017355385A1 (en) 2019-05-30
EP3535272A4 (en) 2020-06-17
BR112019008698A2 (pt) 2019-07-16
PH12019500858A1 (en) 2019-12-02
AU2020227036A1 (en) 2020-09-17
IL266135A (en) 2019-06-30
WO2018085342A1 (en) 2018-05-11
EP3535272A1 (en) 2019-09-11
EA201991069A1 (ru) 2019-10-31
CN109923117A (zh) 2019-06-21
SG11201903723RA (en) 2019-05-30
JP2020500175A (ja) 2020-01-09
MA46728A (fr) 2019-09-11
US20180133223A1 (en) 2018-05-17
KR20190077040A (ko) 2019-07-02

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2020000860A1 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2025001789A (es) Compuestos de pirrolidina
AR101740A1 (es) Terapia de combinación y composiciones
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
AR102463A1 (es) Inhibidor de cinasa aurora a
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
PE20221768A1 (es) Inhibidores de egfr
MX2021009206A (es) Terapias contra el cancer.
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.